KW 045
Alternative Names: KW-045Latest Information Update: 06 Nov 2023
Price :
$50 *
At a glance
- Originator Beijing Kawin Technology Share-Holding
- Class Antivirals; Interferons
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Herpes simplex virus infections; Viral infections
Most Recent Events
- 06 Sep 2023 Phase-I clinical trials in Herpes simplex virus infections in China (unspecified route), prior to September 2023 (Beijing kawin technology share holding pipeline, September 2023)
- 06 Sep 2023 Phase-I clinical trials in Viral infections in China (unspecified route), prior to September 2023 (Beijing kawin technology share holding pipeline, September 2023)